SEC Info - NovaBay Pharmaceuticals, Inc. - ‘10-Q’ for 6/30/19

SEC Info℠

Home

Help

Please Sign In

NovaBay Pharmaceuticals, Inc. – ‘10-Q’ for 6/30/19 – ‘EX-101.SCH’

On: Wednesday, 8/7/19, at 6:53am ET · For: 6/30/19 · Accession #: 1437749-19-15688 · File #: 1-33678

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/07/19  NovaBay Pharmaceuticals, Inc.     10-Q        6/30/19   92:8.8M                                   RDG Filings/FA

Quarterly Report — Form 10-Q — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    875K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     31K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     31K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     27K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     27K 
12: R1          Document And Entity Information                     HTML     57K 
13: R2          Consolidated Balance Sheets (Current Period         HTML    110K 
                Unaudited)                                                       
14: R3          Consolidated Balance Sheets (Current Period         HTML     47K 
                Unaudited) (Parentheticals)                                      
15: R4          Consolidated Statements of Operations and           HTML     89K 
                Comprehensive Loss (Unaudited)                                   
16: R5          Consolidated Statements of Cash Flows (Unaudited)   HTML    138K 
17: R6          Consolidated Statements of Stockholders' Equity     HTML    108K 
                (Unaudited)                                                      
18: R7          Note 1 - Organization                               HTML     40K 
19: R8          Note 2 - Summary of Significant Accounting          HTML    198K 
                Policies                                                         
20: R9          Note 3 - Fair Value Measurements                    HTML    115K 
21: R10         Note 4 - Prepaid Expenses and Other Current Assets  HTML     43K 
22: R11         Note 5 - Inventory                                  HTML     38K 
23: R12         Note 6 - Property and Equipment                     HTML     45K 
24: R13         Note 7 - Accrued Liabilities                        HTML     39K 
25: R14         Note 8 - Commitments and Contingencies              HTML     73K 
26: R15         Note 9 - Related Party Notes Payable                HTML     42K 
27: R16         Note 10 - Convertible Note                          HTML     66K 
28: R17         Note 11 - Warrant Liability                         HTML    101K 
29: R18         Note 12 - Stockholders' Equity                      HTML     64K 
30: R19         Note 13 - Equity-based Compensation                 HTML    135K 
31: R20         Note 14 - License, Collaboration and Distribution   HTML     78K 
                Agreements                                                       
32: R21         Note 15 - Employee Benefit Plan                     HTML     31K 
33: R22         Note 16 - Related Party Transactions                HTML     44K 
34: R23         Note 17 - Subsequent Events                         HTML     41K 
35: R24         Significant Accounting Policies (Policies)          HTML    262K 
36: R25         Note 2 - Summary of Significant Accounting          HTML    119K 
                Policies (Tables)                                                
37: R26         Note 3 - Fair Value Measurements (Tables)           HTML    108K 
38: R27         Note 4 - Prepaid Expenses and Other Current Assets  HTML     43K 
                (Tables)                                                         
39: R28         Note 5 - Inventory (Tables)                         HTML     39K 
40: R29         Note 6 - Property and Equipment (Tables)            HTML     43K 
41: R30         Note 7 - Accrued Liabilities (Tables)               HTML     38K 
42: R31         Note 8 - Commitments and Contingencies (Tables)     HTML     62K 
43: R32         Note 9 - Related Party Notes Payable (Tables)       HTML     35K 
44: R33         Note 10 - Convertible Note (Tables)                 HTML     54K 
45: R34         Note 11 - Warrant Liability (Tables)                HTML     92K 
46: R35         Note 12 - Stockholders' Equity (Tables)             HTML     43K 
47: R36         Note 13 - Equity-based Compensation (Tables)        HTML    102K 
48: R37         Note 14 - License, Collaboration and Distribution   HTML     53K 
                Agreements (Tables)                                              
49: R38         Note 1 - Organization (Details Textual)             HTML     31K 
50: R39         Note 2 - Summary of Significant Accounting          HTML     89K 
                Policies (Details Textual)                                       
51: R40         Note 2 - Summary of Significant Accounting          HTML     38K 
                Policies - Components of Cash, Cash Equivalents,                 
                and Restricted Cash (Details)                                    
52: R41         Note 2 - Summary of Significant Accounting          HTML     42K 
                Policies - Revenues and Accounts Receivable From                 
                Major Distribution Partners and Customers                        
                (Details)                                                        
53: R42         Note 2 - Summary of Significant Accounting          HTML     63K 
                Policies - Calculation of Basic and Diluted EPS                  
                (Details)                                                        
54: R43         Note 2 - Summary of Significant Accounting          HTML     32K 
                Policies - Outstanding Stock Options and Stock                   
                Warrants Excluded From the Diluted Net Loss Per                  
                Share Computation (Details)                                      
55: R44         Note 2 - Summary of Significant Accounting          HTML     50K 
                Policies - Impact of New Standard on Consolidated                
                Balance Sheet (Details)                                          
56: R45         Note 3 - Fair Value Measurements (Details Textual)  HTML     37K 
57: R46         Note 3 - Fair Value Measurements - Assets and       HTML     54K 
                Liabilities Measured at Fair Value on a Recurring                
                Basis (Details)                                                  
58: R47         Note 3 - Fair Value Measurements - Fair Value of    HTML     36K 
                Warrant Liability (Details)                                      
59: R48         Note 4 - Prepaid Expenses and Other Current Assets  HTML     45K 
                - Summary of Prepaid Expenses and Other Current                  
                Assets (Details)                                                 
60: R49         Note 5 - Inventory - Summary of Inventory           HTML     37K 
                (Details)                                                        
61: R50         Note 6 - Property and Equipment (Details Textual)   HTML     28K 
62: R51         Note 6 - Property and Equipment - Summary of        HTML     44K 
                Property and Equipment (Details)                                 
63: R52         Note 7 - Accrued Liabilities - Summary of Accrued   HTML     39K 
                Liabilities (Details)                                            
64: R53         Note 8 - Commitments and Contingencies (Details     HTML     36K 
                Textual)                                                         
65: R54         Note 8 - Commitments and Contingencies - Lease      HTML     40K 
                Expense (Details)                                                
66: R55         Note 8 - Commitments and Contingencies - Schedule   HTML     47K 
                of Future Lease Payments (Details)                               
67: R56         Note 8 - Commitments and Contingencies - Schedule   HTML     38K 
                of Future Lease Payments to Be Received (Details)                
68: R57         Note 9 - Related Party Notes Payable (Details       HTML     50K 
                Textual)                                                         
69: R58         Note 9 - Related Party Notes Payable - Schedule of  HTML     46K 
                related Party Debt (Details)                                     
70: R59         Note 10 - Convertible Note (Details Textual)        HTML     74K 
71: R60         Note 10 - Convertible Note - Key Assumptions Used   HTML     34K 
                to Value the Combined Embedded Derivative                        
                (Details)                                                        
72: R61         Note 10 - Convertible Note - Schedule of            HTML     44K 
                Convertible Note (Details)                                       
73: R62         Note 10 - Convertible Note - Schedule of Maturity   HTML     39K 
                of Convertible Note (Details)                                    
74: R63         Note 11 - Warrant Liability (Details Textual)       HTML    128K 
75: R64         Note 11 - Warrant Liability - The Key Assumptions   HTML     54K 
                Used to Value the Warrants (Details)                             
76: R65         Note 11 - Warrant Liability - Outstanding Warrant   HTML     37K 
                Liability (Details)                                              
77: R66         Note 12 - Stockholders' Equity (Details Textual)    HTML    163K 
78: R67         Note 12 - Stockholders' Equity - Outstanding        HTML     42K 
                Warrants (Details)                                               
79: R68         Note 13 - Equity-based Compensation (Details        HTML    156K 
                Textual)                                                         
80: R69         Note 13 - Equity-based Compensation - Stock         HTML     93K 
                Options Outstanding (Details)                                    
81: R70         Note 13 - Equity-based Compensation -               HTML     40K 
                Weighted-average Assumptions Used in Determining                 
                the Value of Options Granted to Employees and                    
                Directors (Details)                                              
82: R71         Note 13 - Equity-based Compensation -               HTML     39K 
                Weighted-average Assumptions Used in Determining                 
                the Value of Options Granted to Non-employees                    
                (Details)                                                        
83: R72         Note 13 - Equity-based Compensation - Summary of    HTML     35K 
                Stock-based Compensation Expense Included in                     
                Results of Operations (Details)                                  
84: R73         Note 14 - License, Collaboration and Distribution   HTML     98K 
                Agreements (Details Textual)                                     
85: R74         Note 14 - License, Collaboration and Distribution   HTML     45K 
                Agreements - Changes in Assets and Liabilities                   
                (Details)                                                        
86: R75         Note 14 - License, Collaboration and Distribution   HTML     34K 
                Agreements - Total Revenues (Details)                            
87: R76         Note 15 - Employee Benefit Plan (Details Textual)   HTML     28K 
88: R77         Note 16 - Related Party Transactions (Details       HTML     60K 
                Textual)                                                         
89: R78         Note 17 - Subsequent Events (Details Textual)       HTML     42K 
91: XML         IDEA XML File -- Filing Summary                      XML    177K 
90: EXCEL       IDEA Workbook of Financial Reports                  XLSX     92K 
 6: EX-101.INS  XBRL Instance -- nby-20190630                        XML   2.60M 
 8: EX-101.CAL  XBRL Calculations -- nby-20190630_cal                XML    162K 
 9: EX-101.DEF  XBRL Definitions -- nby-20190630_def                 XML   1.71M 
10: EX-101.LAB  XBRL Labels -- nby-20190630_lab                      XML   1.32M 
11: EX-101.PRE  XBRL Presentations -- nby-20190630_pre               XML   1.74M 
 7: EX-101.SCH  XBRL Schema -- nby-20190630                          XSD    274K 
92: ZIP         XBRL Zipped Folder -- 0001437749-19-015688-xbrl      Zip    232K

‘EX-101.SCH’ — XBRL Schema — nby-20190630

This Exhibit is an XBRL XML File.

<?xml version="1.0" standalone="no" encoding="windows-1252"?>

<xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nby="http://www.novabaypharma.com/20190630" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novabaypharma.com/20190630">

<xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>

<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>

<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>

<xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>

<xsd:annotation>

<xsd:appinfo>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20190630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20190630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20190630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>

<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nby-20190630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>

<link:roleType id="statement-document-and-entity-information" roleURI="http://www.novabaypharma.com/20190630/role/statement-document-and-entity-information">

<link:definition xmlns="http://www.xbrl.org/2003/linkbase"> 000 - Document - Document And Entity Information </link:definition>